Overview
Description
About
Fulford
York, YO19 4FE
Latest press releases
Issued on behalf of Oncolytics Biotech Inc.
USANewsGroup.com News Commentary
VANCOUVER, BC, Dec. 31, 2025 /CNW/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy selection now enables oncology pharmacists and clinicians to match treatments to tumor-specific characteristics rather than relying on blind, one-size-fits-all protocols[2]. This convergence of diagnostic precision and therapeutic targeting defines the investment thesis for Oncolytics Biotech Inc. (NASDAQ: ONCY), Exact Sciences Corp. (NASDAQ: EXAS), Veracyte, Inc. (NASDAQ: VCYT), Hologic, Inc. (NASDAQ: HOLX), and Personalis, Inc. (NASDAQ: PSNL).
The AI in oncology market is projected to explode from $5.1 billion in 2024 to $53.1 billion by 2034, expanding at a remarkable 26.4% CAGR as machine learning transforms diagnostic accuracy[3]. Hospitals have implemented AI-powered patient monitoring systems across healthcare institutions globally[4], supporting real-time clinical decision-making that bridges the gap between early detection and personalized treatment selection.
Oncolytics Biotech Inc. (NASDAQ: ONCY) is a clinical-stage biotech developing pelareorep, an investigational immunotherapy designed to activate the immune system against cancer. The company recently announced breakthrough efficacy data showing pelareorep achieved a 33% objective response rate in second-line KRAS-mutant metastatic colorectal cancer patients when combined with standard chemotherapy. This triples the historical 6-11% response rate for chemotherapy alone in this difficult-to-treat patient population.
"These results are extremely encouraging," said Dr. Sanjay Goel, Professor of Medicine at Rutgers Cancer Institute of New Jersey. "Achieving a 33% ORR in KRAS-mutant MSS colorectal cancer is highly unusual in this setting and warrants immediate further study."
The data establishes pelareorep as a precision immunotherapy that delivers meaningful clinical benefit over current treatment standards. Translational analysis revealed that pelareorep increases KRAS-mutant-specific T-cell populations, providing mechanistic proof that it targets this genetic mutation, driving many colorectal and other gastrointestinal cancers.
Equally compelling anal cancer results showed a 30% response rate in second-line squamous cell anal carcinoma, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in this setting. The median duration of response reached 15.5 months compared to 9.5 months for standard care, with two durable complete responses demonstrating pelareorep's ability to achieve deep, lasting tumor control.
"Colorectal cancer is the core of our emerging GI tumor platform strategy for pelareorep, with a projected total addressable market of $20 billion by 2033," said Jared Kelly, CEO of Oncolytics Biotech. "Pelareorep has clearly demonstrated the potential to become a transformational new treatment option in this underserved setting."
The company plans to sponsor a controlled study in second-line KRAS-mutant colorectal cancer following consultation with key opinion leaders and regulatory authorities. This represents a critical advancement, as Oncolytics will control the data generated and update investors and potential partners at its discretion.
Oncolytics recently established a Gastrointestinal Tumor Scientific Advisory Board to guide registration strategy across pancreatic, colorectal, and anal cancers. The board includes leading oncologists from Rutgers Cancer Institute, Northwestern University, and the principal investigator of the company's pivotal GOBLET study.
Oncolytics has also secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the only immunotherapy registration trial currently planned for this disease. Pelareorep holds both Fast Track and Orphan Drug designations from the FDA for pancreatic cancer.
CEO Jared Kelly and Chief Business Officer Andrew Aromando were both crucial contributors to Ambrx Biopharma's $2 billion acquisition by Johnson & Johnson, demonstrating proven ability to advance assets through value-creating transactions.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Exact Sciences (NASDAQ: EXAS) announced results from its Oncodetect molecular residual disease test demonstrating strong prognostic performance in early triple-negative breast cancer, one of the most aggressive breast cancer subtypes. The NSABP B-59 substudy, conducted with the NSABP Foundation and German Breast Group, showed post-surgery MRD-positive status was associated with a 30-fold higher risk of distant recurrence compared to MRD-negative patients. Among 147 analyzed patients, 95% who remained ctDNA-negative after surgery stayed free of distant recurrence at 3 years.
"The NSABP Foundation is proud to collaborate on this impactful study," said Dr. Norman Wolmark, chairman, NSABP Foundation. "The strength of these data, particularly the clear separation in distant recurrence curves, highlight the prognostic power of ctDNA and its potential to guide post-surgical management strategies for high-risk breast cancer."
The data, representing one of the largest TNBC MRD datasets analyzed to date, were presented at the San Antonio Breast Cancer Symposium. Exact Sciences plans to submit the data to MolDx in support of Medicare coverage and is also collaborating with the NSABP Foundation on NSABP B-64, a prospective registry trial enrolling 1,800 participants across all breast cancer subtypes.
Veracyte, Inc. (NASDAQ: VCYT) announced the first publications using its Afirma GRID research tool to define the future of thyroid nodule evaluation. The studies, published in Frontiers in Endocrinology and Surgery, used whole-transcriptome-derived data to develop signatures that may provide enhanced prognostic information prior to surgery. In the Cleveland Clinic study of 445 thyroid samples, researchers identified two molecular signatures with potential clinical utility, including an invasion signature predicting a 30% greater likelihood of intermediate or high-risk cancer.
"We introduced Afirma GSC in 2017 to primarily help patients with indeterminate thyroid nodules--those that were not clearly benign or malignant--avoid unnecessary diagnostic surgery," said Dr. Joshua Klopper, Veracyte's medical director for Endocrinology. "Now, Veracyte is working to help clinical researchers better answer the next critical question for thyroid nodule care: for those patients whose nodules are likely cancerous, how much surgery is needed?"
The Afirma GRID database contains sequencing data from over 21,000 expressed genes for more than 200,000 patients with thyroid nodules. While the studies don't yet provide necessary validation for clinical use, they highlight signatures with potential to guide treatment decisions and extent-of-surgery discussions.
Hologic (NASDAQ: HOLX) announced new data demonstrating its Genius AI Detection mammography solution flagged approximately one-third of breast cancer cases initially interpreted as negative in a retrospective analysis of 7,500 digital breast tomosynthesis screening exams at Massachusetts General Hospital. The AI technology accurately identified the location where breast cancer was subsequently diagnosed in these false-negative cases, and flagged almost 90% of the 500 breast cancer cases previously identified by radiologists while correctly localizing their locations. The study analyzed exams performed between 2016 and 2019, with the AI algorithm showing particular effectiveness in identifying invasive ductal carcinomas and lymph node-positive cancers.
"In this study, not only did the AI identify the case as suspicious and warranting additional review, but it also correctly localized the region of interest," said Dr. Manisha Bahl, Associate Director of Quality for Breast Imaging at Mass General Brigham and Associate Professor of Radiology at Harvard Medical School. "While additional research is needed, these findings are promising and highlight AI's tremendous potential to redefine breast cancer detection in the years ahead."
Hologic's deep learning algorithm draws from a large, diverse patient database, providing intelligence for concurrent reading at radiologists' workstations. The company continues advancing its AI-powered screening technology designed to locate lesions likely to represent breast cancer and support decisive interpretation.
Personalis (NASDAQ: PSNL) announced a new publication in Clinical Cancer Research demonstrating its NeXT Personal ultra-sensitive molecular residual disease assay can effectively predict patient outcomes across diverse cancers and immunotherapy modalities. The study analyzed 202 patients with stage IV solid tumors spanning 24 cancer types treated with immune checkpoint inhibitors. The test detected ctDNA in 98% of patients at baseline and showed patients with durable molecular clearance for at least 180 days achieved 100% overall survival.
"Immunotherapy has revolutionized cancer care, but response patterns can be difficult to interpret using imaging alone," said Dr. Rodrigo Toledo, Group Leader of the Biomarkers and Clonal Dynamics Laboratory at VHIO and senior author. "Our findings show that ultrasensitive ctDNA dynamics provide a clear, early molecular view of benefit or non-response, offering a powerful tool to guide patient management across a broad spectrum of solid tumors."
The NeXT Personal test tracks up to 1,800 tumor-specific variants unique to each patient, achieving ultrasensitive detection of circulating tumor DNA. Patients with decreasing ctDNA levels early in treatment had significantly higher overall survival, while those with increasing ctDNA had a zero percent overall response rate.
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES CITED:
- https://www.openpr.com/news/4272820/precision-oncology-market-set-for-transformational-growth
- https://www.pharmacytimes.com/view/sabcs-2025-roundup-advancing-therapy-and-precision-care-in-breast-cancer
- https://media.market.us/global-ai-in-oncology-market-news/
- https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-oncology-market-report
Logo: https://mma.prnewswire.com/media/2838876/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/smart-oncology-5-stocks-chasing-the-317b-prize-302651229.html
Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and geographic region play a major role in shaping patient attitudes—and that the score could be used to tailor AI-driven tools in a way that improves both outcomes and satisfaction. With the global AI healthcare market projected to exceed $110 billion by 2030, companies such as Avant Technologies, Inc. (OTCQB: AVAI), Tevogen Bio Holdings Inc. (NASDAQ: TVGN), Microsoft Corporation (NASDAQ: MSFT), Personalis, Inc. (NASDAQ: PSNL), and Tempus AI, Inc. (NASDAQ: TEM).
AI could inject an additional $461 billion into the healthcare sector by 2035, according to Accenture, as it races past the $2.26 trillion mark. This shift isn't just about diagnostics or robotics—it's about rewiring the entire healthcare ecosystem from the inside out, and multiple companies are positioning themselves to capitalize on the shift.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech reached a pivotal regulatory milestone in their pursuit of AI-driven healthcare disruption—completing a key pre-submission meeting with the U.S. Food and Drug Administration (FDA) for their flagship diagnostic platform, Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases.
"We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.
The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI, which screens for diabetic retinopathy using artificial intelligence and retinal imaging. The session provided Ainnova and its clinical trial partner, Fortrea, with detailed guidance from the FDA, including feedback on study design, number of participating clinics, retinologist involvement, and trial execution strategy. With this roadmap in place, the team can now finalize its U.S. trial plan and begin preparing for formal data collection—bringing Vision AI closer to commercialization in the world's largest healthcare market.
"This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care."
The FDA development comes just as Avant and Ainnova officially launch a first-of-its-kind chronic care model across Latin America, focused on preventive screening for patients with diabetes and other systemic conditions. The initiative—now live through pilot programs with Grupo Dökka's Fischel and La Bomba pharmacy chains—offers free, walk-in retinal risk assessments at local pharmacies. It's a bold attempt to break down long-standing access barriers by bypassing the need for specialist appointments altogether.
Instead, patients receive real-time results through Ainnova's AI platform, with those flagged as "at risk" referred seamlessly into a growing network of clinics and specialists. The model has already gained traction among pharmacies, insurers, and pharmaceutical partners—demonstrating a rare alignment of incentives across the healthcare ecosystem.
Over 30% of diabetics develop diabetic retinopathy, a condition that's treatable when caught early, but which remains the leading cause of preventable blindness worldwide. The Vision AI system enables earlier, lower-cost intervention by offering high-accuracy screenings without requiring an ophthalmologist on site.
The U.S. FDA clearance pathway and the Latin American commercial rollout are advancing in parallel, with Avant playing a key strategic role. Through Ai-nova Acquisition Corp., the company co-founded and structured, Avant holds global licensing rights to Ainnova's platform and stands to benefit from the full spectrum of commercial activity. The Latin America pilot programs—already live and expanding—are expected to deliver measurable near-term revenue, while U.S. approval would unlock a massive new addressable market.
Meanwhile, Avant is also preparing a new standalone venture that would house a potential therapeutic candidate for diabetes. The goal is to consolidate leadership, data, and IP under one unified structure—eliminating holding company inefficiencies and streamlining execution across diagnostics and treatment.
Beyond diabetic retinopathy, Ainnova's roadmap includes a cloud-connected retinal camera designed for rural or low-resource clinics, as well as future modules that may detect early signs of Alzheimer's, cardiovascular disease, and other chronic conditions through retinal or blood biomarker analysis. Vision AI could become not just a diagnostic tool, but a frontline system for early detection across multiple diseases.
The companies continue to explore structural simplification as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech—bringing all IP, leadership, and commercial rights under one public umbrella. That move would offer investors direct exposure to the entire tech stack and revenue funnel, while further integrating operations between the two firms.
CONTINUED... Read this and more news for Avant Technologies at:
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) and Microsoft Corporation (NASDAQ: MSFT) alongside Databricks, have developed the alpha version of PredicTcell™, a next-gen AI model designed to transform early drug discovery. By dramatically accelerating protein sequence analysis and immunologic target identification, the platform has the potential to save billions in research costs and compress timelines from months to hours.
"This achievement underscores Tevogen.AI's commitment to revolutionizing therapeutic development through AI-driven innovation," said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. "By significantly accelerating identification of immunologically active targets, PredicTcell enables a more efficient transition into clinical research, ultimately benefiting patients. We look forward to enhancing our datasets to include the spectrum of virology, oncology and neurology to further enhance the PredicTcell platform."
Built on a terabyte-scale dataset covering nearly a billion genetic and proteomic data points, the system leverages transformer-based AI to improve accuracy and reduce dependency on traditional wet lab testing.
"Through the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentially resulting in better accuracy and reduced time for wet lab testing," said Dr. Neal Flomenberg, Chief Research and Scientific Officer of Tevogen.
The initial focus was virology, but the model is now being expanded to cover oncology and potentially neurology. Tevogen believes this foundational platform could yield major gains in both clinical efficiency and commercial opportunity for early adopters.
Personalis, Inc. (NASDAQ: PSNL), and Tempus AI, Inc. (NASDAQ: TEM) have deepened their collaboration to expand access to AI-powered MRD testing through the NeXT Personal® platform, now adding colorectal cancer to their existing portfolio.
"This deepened collaboration is a key component of our 'Win in MRD' strategy," said Chris Hall, CEO of Personalis. "Every day, thousands of cancer survivors live with the uncertainty of whether their cancer will return. By expanding our collaboration with Tempus to include CRC, we're bringing peace of mind to more patients while building the evidence needed for broad reimbursement coverage for multiple indications."
The updated agreement extends through 2029 and aims to accelerate commercial adoption across four key cancer types. Backed by compelling VICTORI study data, the AI-driven test offers ultra-sensitive detection of recurrence, providing oncologists with a more precise and timely monitoring tool.
"The clinical performance we're seeing across cancer types demonstrates that ultra-sensitive detection fundamentally changes how we can monitor cancer patients," added Hall. "With Tempus' reach to over 50% of U.S. oncologists, we're accelerating access to technology that gives both physicians and patients the information they need when it matters most."
The collaboration reflects a shared commitment to leveraging AI for personalized, proactive cancer care across multiple stages of treatment.
CONTACT:
Equity Insider
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo - https://mma.prnewswire.com/media/2644233/5418904/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/from-clinics-to-cancer-labs-ai-is-unlocking-a-new-100b-era-in-medicine-302507341.html
